drugset
drugset / Trial / NCT00783835

Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00783835 ↗

Phase 4 Completed 60 enrolled Janssen-Cilag Farmaceutica Ltda.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety and to assess the impact of the treatment on quality of life of long-acting methylphenidate in adult participants with Attention Deficit Hyperactivity Disorder (ADHD). ADHD is a clinical condition beginning in childhood and is characterized by inadequate levels of attention, hyperactivity and impulsiveness.

Timeline

Start
2008-02
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Long-Acting Methylphenidate Unknown 18 mg Oral
Subject Long-Acting Methylphenidate Unknown 36 mg Oral
Subject Long-Acting Methylphenidate Unknown 54 mg Oral
Subject Long-Acting Methylphenidate Unknown 76 mg Oral

Indications

attention deficit-hyperactivity disorder